Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633012 | 0.91 | GPR119 (0.45) | MAPK1GPR119SCN9AGRM5GRM1 | |
| SCHEMBL16640483 | 0.91 | GPR119 (0.45) | MAPK1GPR119SCN9AGRM5GRM1 | |
| SCHEMBL31444393 | 0.89 | GPR119 (0.43) | MAPK1GPR119SCN9AUSP30RORC | |
| SCHEMBL25354916 | 0.88 | MAPK1 (0.48) | MAPK1GPR119USP30RORC | |
| SCHEMBL30453635 | 0.88 | MAPK1 (0.48) | MAPK1GPR119USP30RORC | |
| SCHEMBL30453849 | 0.88 | MAPK1 (0.48) | MAPK1GPR119USP30RORC | |
| SCHEMBL16640393 | 0.86 | SMN1; SMN2 (0.45) | MAPK1GPR119USP30TP53MAPT | |
| SCHEMBL22086319 | 0.86 | GPR119 (0.45) | MAPK1GPR119USP30MEN1KMT2A | |
| SCHEMBL22086326 | 0.86 | GPR119 (0.45) | MAPK1GPR119USP30MEN1KMT2A | |
| SCHEMBL29372092 | 0.86 | GPR119 (0.45) | MAPK1GPR119USP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143163-A1 | ANTAGONISTS OF GPR39 PROTEIN | Oregon Health & Science University (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222858-A1 | ANTAGONISTS OF GPR39 PROTEIN | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | MAPK1 2451/4885GPR119 449/4885SCN9A 3906/4885 |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | MAPK1 3174/4885GPR119 3/4885SCN9A 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.